Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.

BACKGROUND: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F polysaccharides individually conjugated to CRM197 was evaluated in a randomized, double-blind, controlled infant study....

Full description

Bibliographic Details
Main Authors:	Snape, MD, Klinger, C, Daniels, E, John, T, Layton, H, Rollinson, L, Pestridge, S, Dymond, S, Galiza, E, Tansey, S, Scott, D, Baker, SA, Jones, T, Yu, L, Gruber, W, Emini, E, Faust, SN, Finn, A, Heath, P, Pollard, A
Format:	Journal article
Language:	English
Published:	2010

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.

Similar Items